Cargando…

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Jonathan, Peschel, Georg, Müller, Martina, Schacherer, Doris, Wiest, Reiner, Weigand, Kilian, Buechler, Christa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069657/
https://www.ncbi.nlm.nih.gov/pubmed/33920491
http://dx.doi.org/10.3390/jcm10081621
_version_ 1783683288494243840
author Grimm, Jonathan
Peschel, Georg
Müller, Martina
Schacherer, Doris
Wiest, Reiner
Weigand, Kilian
Buechler, Christa
author_facet Grimm, Jonathan
Peschel, Georg
Müller, Martina
Schacherer, Doris
Wiest, Reiner
Weigand, Kilian
Buechler, Christa
author_sort Grimm, Jonathan
collection PubMed
description Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of this study was to determine serum PCSK9 concentrations during and after DAA therapy to identify associations with LDL levels. Serum PCSK9 was increased in 82 chronic HCV-infected patients compared to 55 patients not infected with HCV. Serum PCSK9 was low in HCV patients with liver cirrhosis, but patients with HCV-induced liver cirrhosis still exhibited higher serum PCSK9 than patients with non-viral liver cirrhosis. Serum PCSK9 correlated with measures of liver injury and inflammation in cirrhotic HCV patients. In patients without liver cirrhosis, a positive association of serum PCSK9 with viral load existed. Serum PCSK9 was not different between viral genotypes. Serum PCSK9 did not correlate with LDL levels in HCV patients irrespective of cirrhotic status. Serum PCSK9 was reduced, and LDL was increased at four weeks after DAA therapy start in non-cirrhotic HCV patients. Serum PCSK9 and LDL did not change upon DAA treatment in the cirrhotic group. The rapid decline of PCSK9 after the start of DAA therapy in conjunction with raised LDL levels in non-cirrhotic HCV patients shows that these changes are not functionally related.
format Online
Article
Text
id pubmed-8069657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80696572021-04-26 Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy Grimm, Jonathan Peschel, Georg Müller, Martina Schacherer, Doris Wiest, Reiner Weigand, Kilian Buechler, Christa J Clin Med Article Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of this study was to determine serum PCSK9 concentrations during and after DAA therapy to identify associations with LDL levels. Serum PCSK9 was increased in 82 chronic HCV-infected patients compared to 55 patients not infected with HCV. Serum PCSK9 was low in HCV patients with liver cirrhosis, but patients with HCV-induced liver cirrhosis still exhibited higher serum PCSK9 than patients with non-viral liver cirrhosis. Serum PCSK9 correlated with measures of liver injury and inflammation in cirrhotic HCV patients. In patients without liver cirrhosis, a positive association of serum PCSK9 with viral load existed. Serum PCSK9 was not different between viral genotypes. Serum PCSK9 did not correlate with LDL levels in HCV patients irrespective of cirrhotic status. Serum PCSK9 was reduced, and LDL was increased at four weeks after DAA therapy start in non-cirrhotic HCV patients. Serum PCSK9 and LDL did not change upon DAA treatment in the cirrhotic group. The rapid decline of PCSK9 after the start of DAA therapy in conjunction with raised LDL levels in non-cirrhotic HCV patients shows that these changes are not functionally related. MDPI 2021-04-11 /pmc/articles/PMC8069657/ /pubmed/33920491 http://dx.doi.org/10.3390/jcm10081621 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grimm, Jonathan
Peschel, Georg
Müller, Martina
Schacherer, Doris
Wiest, Reiner
Weigand, Kilian
Buechler, Christa
Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title_full Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title_fullStr Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title_full_unstemmed Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title_short Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
title_sort rapid decline of serum proprotein convertase subtilisin/kexin 9 (pcsk9) in non-cirrhotic patients with chronic hepatitis c infection receiving direct-acting antiviral therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069657/
https://www.ncbi.nlm.nih.gov/pubmed/33920491
http://dx.doi.org/10.3390/jcm10081621
work_keys_str_mv AT grimmjonathan rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT peschelgeorg rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT mullermartina rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT schachererdoris rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT wiestreiner rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT weigandkilian rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy
AT buechlerchrista rapiddeclineofserumproproteinconvertasesubtilisinkexin9pcsk9innoncirrhoticpatientswithchronichepatitiscinfectionreceivingdirectactingantiviraltherapy